Prolight Diagnostics (PRLD) Q4 2025 earnings summary

Executive summary

• Achieved key milestones in commercializing the Psyros platform, including assay design freeze and positive patient data demonstrating laboratory-grade performance in whole blood.

• Presented a fully functional commercial prototype at an international congress, receiving strong interest from potential partners and end users.

• Strengthened IP position with new patents granted in Europe and Japan.

• Secured SEK 100 million in funding through a fully subscribed rights issue, supporting completion of Psyros and pilot manufacturing preparations.

• Entering 2026 focused on final system verification, manufacturing validation, and clinical performance study ahead of a planned 2027 commercial launch.

Financial highlights

• Net sales remained at 0 SEK for both Q4 and the full year 2025, unchanged from the previous year.

• Other operating income was 10,670 TSEK in Q4 (down from 15,317 TSEK) and 26,854 TSEK for the year (up from 19,133 TSEK).

• Operating profit (EBIT) was -13,060 TSEK in Q4 (down from 1,492 TSEK) and -53,249 TSEK for the year (down from -27,270 TSEK).

• Profit after tax was -12,123 TSEK in Q4 (down from 2,014 TSEK) and -49,708 TSEK for the year (down from -26,937 TSEK).

• Earnings per share before and after dilution: -1.01 SEK in Q4 (vs. -0.29 SEK) and -4.13 SEK for the year (vs. -0.04 SEK).

• Cash flow from operating activities was -11,546 TSEK in Q4 (vs. 6,448 TSEK) and -37,005 TSEK for the year (vs. -27,946 TSEK).

• Cash and cash equivalents at year-end were 40,606 TSEK (up from 15,734 TSEK).

Outlook and guidance

• Focus for 2026 is on final system verification, manufacturing process validation, pilot production, and initiation of a European multicentre clinical performance study.

• Commercial launch targeted for 2027, with scalable cartridge production capacity established.